AtriCure CTO Sells 3,657 Shares
Privitera executed the sale under a pre-established Rule 10b5-1 trading plan.
Overview
Salvatore Privitera, Chief Technical Officer of AtriCure (NASDAQ:ATRC), sold 3,657 shares of common stock on Sept. 8, 2026, as disclosed in a recent SEC Form 4 filing.
Transaction value based on SEC Form 4 weighted average sale price ($55); post-transaction value based on Sept. 8, 2026, market close ($53.73).
Details
AtriCure is a mid-cap medical device company with a market capitalization of $2.7 billion and TTM revenues of $569.6 million, demonstrating strong operational momentum. The company maintains a focused competitive position in the specialized cardiac ablation market through proprietary radiofrequency and multifunctional device technologies that enable both therapeutic intervention and real-time diagnostic assessment during surgical procedures. With 1,350 employees and a global distribution footprint, AtriCure leverages its differentiated product portfolio and clinical expertise to capture market share in the growing cardiac surgery and arrhythmia treatment segments.
Source
Originally published at www.fool.com.